Everolimus plus exemestane as first-line therapy in HR(+), HER2(−) advanced breast cancer in BOLERO-2

The present exploratory analysis examined the efficacy, safety, and quality-of-life effects of everolimus (EVE) + exemestane (EXE) in the subgroup of patients in BOLERO-2 whose last treatment before study entry was in the (neo)adjuvant setting. In BOLERO-2, patients with hormone-receptor-positive (H...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Beck, J. Thaddeus, Hortobagyi, Gabriel N., Campone, Mario, Lebrun, Fabienne, Deleu, Ines, Rugo, Hope S., Pistilli, Barbara, Masuda, Norikazu, Hart, Lowell, Melichar, Bohuslav, Dakhil, Shaker, Geberth, Matthias, Nunzi, Martina, Heng, Daniel Y. C., Brechenmacher, Thomas, El-Hashimy, Mona, Douma, Shyanne, Ringeisen, Francois, Piccart, Martine
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2013
Assuntos:
Clinical Trial
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3907668/
https://ncbi.nlm.nih.gov/pubmed/24362951
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-013-2814-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados